CAFC Enrichment After PBPC Drug Exposure
| . | Percent of Cells Killed . | CAFC Frequency per Viable Cell Seeded . |
|---|---|---|
| Unmanipulated apheresis cells | 0 | 1/10,280 (±1,042) |
| Control cells (enriched PBPCs) | 0 | 1/203 (±62) |
| Taxol (7.5 ng/mL) | 56 ± 9 | 1/89 (±33) |
| Mafosfamide (100 μg/mL) | 68 ± 11 | 1/69 (±27) |
| Taxol and mafosfamide | 88 ± 12 | 1/18 (±10) |
| 5FU, IL-3, SCF | 93 ± 9 | 1/14 (±7) |
| . | Percent of Cells Killed . | CAFC Frequency per Viable Cell Seeded . |
|---|---|---|
| Unmanipulated apheresis cells | 0 | 1/10,280 (±1,042) |
| Control cells (enriched PBPCs) | 0 | 1/203 (±62) |
| Taxol (7.5 ng/mL) | 56 ± 9 | 1/89 (±33) |
| Mafosfamide (100 μg/mL) | 68 ± 11 | 1/69 (±27) |
| Taxol and mafosfamide | 88 ± 12 | 1/18 (±10) |
| 5FU, IL-3, SCF | 93 ± 9 | 1/14 (±7) |
PBPCs were collected by apheresis from mobilized cancer patients and first enriched by immunoaffinity removal of lineage-positive cells. At the end of the enrichment procedure, CD34+ cell recovery was 53% to 83%, and purity in the range 68% to 96%. The percent of CD34+ cells killed by drug exposure was evaluated by flow cytometry, CAFC frequency was evaluated on week 5 by LDA. Results are expressed as mean (±SD), n = 7.
Abbreviations: CAFC, cobblestone area-forming cell; PBPC, peripheral blood progenitor cell; FU, Fluorouracil; IL, interleukin; SCF, stem cell factor; LDA, limiting dilution analysis; SD, Standard deviation.